KemPharm announced changes to its Board of Directors and executive leadership team as part of the company’s ongoing business transformation initiatives. Effective immediately, Matthew Plooster, who has been serving as an independent member of the Board of Directors, has been appointed to serve as Chairman of the Board of Directors. Richard Pascoe, who has been serving as Executive Chairman, will transition into the role of CEO and remains a member of the Board of Directors. Travis Mickle, Ph.D., who is co-founder and has been serving as President and CEO, will transition to the role of President and will also remain a member of the Board of Directors until the company’s 2023 Annual Meeting of Stockholders. Thereafter, Dr. Mickle will continue to support the Company’s pipeline build and the planned resubmission of the arimoclomol New Drug Application as a scientific advisor. Additionally, Joshua Schafer has been appointed to the newly created role of Chief Commercial Officer and Executive Vice President of Business Development.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KMPH:
- KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
- KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
- KemPharm initiates Phase 2 trial evaluating KP1077
- KemPharm Announces Appointment of Christopher Posner as New Independent Director
- KemPharm appoint Christopher Posner to board of directors
